16 January, 2017

Compliance Expert Ann Cooreman joins Trans-Hit Bio Europe

Trans-Hit Bio is pleased to announce that world class biospecimen compliance expert, Dr. Ann Cooreman, has joined THB Europe.

Ann holds an MA from Antwerp University (Antwerp, Belgium), and a PhD from the University of Oregon (Eugene, OR). Following on from various postdoctoral fellowships, she started her career in the Biobank field as a Project Manager for Scottish Biomedical with the primary responsibility of setting up a Tissue Bank. Afterwards Ann co-founded and led Tissue Solutions Ltd. (Glasgow, Scotland) where she had a variety of corporate, business development, and operational responsibilities and developed this company into a top 3 service provider in Europe. While there, she supervised hundreds of projects for high profile clients, establishing privileged relationships with the most prestigious academic clinical sites and biobanks. Her company was the first biospecimen procurement service company to obtain the ISO 9001 certification. When she sold her interests in the company in 2015, Ann became an independent consultant in ethics and regulatory affairs advising a number of academic and commercial entities.

Ann is responsible for overseeing regulatory, ethical, and quality assurance issues and will also be instrumental in the development of THB’s European branch, partnering with key clients and biorepositories.

With a partnered network of academic biobanks employing 18 CRAs and nurses in the field to collect from over 100 clinical sites in countries such as France, Germany, Italy, Poland, the UK, Russia and Ukraine, supported by 3 PhD qualified THB staff based in Europe, THB has developed an unrivaled presence in this part of the world.

Commenting on her decision, Dr. Ann Cooreman said “I am very pleased to join THB which I consider the gold standard in the biospecimen procurement CRO segment.  Not only do they lead the field in terms of size of network and revenue but more importantly THB is the flagship in terms of traceability and ethics. In this respect, THB is hugely different from brokerage firms who sell biospecimens off the shelf that cannot even be guaranteed to be unique patient sample biospecimens.  As a result of THB’s policy of transparency, many tier 1 academic sites don’t even want to hear any name other than THB.”

Dr. Pascal Puchois, THB Founder and CEO added “I have known Ann for many years when she was heading a competitive firm in the UK. I have always listened to her lectures and advice carefully.  She has what I believe to be a unique capacity to utilize compliance to guidelines as a tool rather than a constraint in the development of business relationships based on mutual trust.  We share the vision that biospecimen procurement is not a commodity business but a research activity”.